[4] Icahn considered his investment and intervention into Hologic to have been a success, with his nominees to the board of directors resigning on March 3, 2016[5] and exiting his position by May 16, 2016.

[7] On November 20, 2019, Hologic announced the divestment of Cynosure to Clayton, Dubilier & Rice for $205 million;[8] this was completed on December 30, 2019.

[12] In June 2020, Hologic collaborated with Grifols, a global producer of plasma-driven medicines, to increase Spain's testing capacity for COVID-19.

[13] In November 2020, Hologic won a $119 million contract from the U.S. Department of Health and Human Services and the Department of Defense to help expand production facilities in three states, Wisconsin, Maine, and California, with the goal to provide 13 million COVID tests per month by January 2022.

[17] In April 2021, the company announced it will acquire Mobidiag, a molecular diagnostics firm with multiplex technology, for $795 million.